Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data

INTRODUCTION: We present the results of real-life tests conducted in adults affected by psoriatic arthritis (PsA) with mild cutaneous involvement to evaluate the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent approved in Europe for the treatment of rheumatoid arthrit...

Descripción completa

Detalles Bibliográficos
Autores principales: Dattola, Annunziata, Cannizzaro, Maria Vittoria, Mazzeo, Mauro, Bianchi, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698207/
https://www.ncbi.nlm.nih.gov/pubmed/29139035
http://dx.doi.org/10.1007/s13555-017-0208-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698207/
https://www.ncbi.nlm.nih.gov/pubmed/29139035
http://dx.doi.org/10.1007/s13555-017-0208-z

Ejemplares similares